Pharmaceutical Company Travere Receives FDA Approval for Kidney Medication
Travere Therapeutics, a pharmaceutical company specializing in rare diseases, achieved a milestone in the first half of 2026 with full FDA approval for its drug FILSPARI to treat two serious kidney diseases. The company achieved its first profitable quarter and simultaneously completed licensing deals.